Anti-BCMA Immuno-nanoPET Radiotracers for Improved Detection of Multiple Myeloma.
Fiche publication
Date publication
octobre 2021
Journal
Advanced healthcare materials
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PIVOT Xavier, Dr DETAPPE Alexandre
Tous les auteurs :
Thomas E, Mathieu C, Moreno-Gaona P, Mittelheisser V, Lux F, Tillement O, Pivot X, Ghoroghchian PP, Detappe A
Lien Pubmed
Résumé
Current clinical imaging modalities for the sensitive and specific detection of multiple myeloma (MM) rely on nonspecific imaging contrast agents based on gadolinium chelates for magnetic resonance imaging (MRI) or for F-FDG-directed and combined positron emission tomography (PET) and computed tomography (CT) scans. These tracers are not, however, able to detect minute plasma cell populations in the tumor niche, leading to false negative results. Here, we sought to develop a novel PET-based anti-BCMA nanoplatform labeled with Cu to improve the monitoring of these cells in both the spine and femur and to compare its sensitive and specificity to more conventional immunoPET ( Cu labeled anti-BCMA antibody) and passively targeted PET radiotracers ( CuCl and F-FDG). This proof-of-concept preclinical study confirmed that in conjugating up to 4 times more radioisotopes per antibody with the immuno-nanoPET platform we were able to observed a ∼3-fold improvement in the sensitivity and ∼2-fold improvement in the specificity of PET to detect tumor cells in an orthotopic model of MM when compared to the traditional immunoPET approach. We anticipate that when combined with tumor biopsy, and immuno-nanoPET platform may improve the management of patients with MM. This article is protected by copyright. All rights reserved.
Mots clés
diagnostics, multiple myeloma, positron emission tomography, targeted-nanoparticle
Référence
Adv Healthc Mater. 2021 Oct 28;:e2101565